SCHEMBL10192155

SCHEMBL10192155

CCCNC(=O)N1CCc2cc(C)ccc21

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.61
HTR2A P28223 1/20 0.54
HTR2C P28335 1/20 0.54
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
ADRB2 P07550 2/20 0.52
ADRB1 P08588 2/20 0.52
ADRB3 P13945 2/20 0.52
KDM4E B2RXH2 2/20 0.51
TP53 P04637 5/20 0.48
MAPT P10636 4/20 0.47
DRD2 P14416 1/20 0.47
DRD4 P21917 1/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
NFKB1 P19838 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
ALDH1A1 P00352 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7042419 0.92 NOTUM (0.58) NOTUMHTR2AHTR2CMEN1KMT2A
SCHEMBL10192165 0.89 NOTUM (0.64) NOTUMHTR2AHTR2CMEN1KMT2A
SCHEMBL30204966 0.82 MAPT (0.61) NOTUMMEN1KMT2ATP53MAPT
SCHEMBL15448489 0.81 NOTUM (0.69) NOTUMHTR2AHTR2CMEN1KMT2A
SCHEMBL16479228 0.79 NOTUM (0.66) NOTUMMEN1KMT2AKDM4ETP53
SCHEMBL10192159 0.78 NOTUM (0.64) NOTUMHTR2AHTR2CMEN1KMT2A
SCHEMBL17676474 0.77 NOTUM (0.62) NOTUMMEN1KMT2AADRB2ADRB1
SCHEMBL423295 0.76 NOTUM (1.00) NOTUMMEN1KMT2AKDM4ETP53
SCHEMBL14826631 0.76 HTR2C (0.74) NOTUMHTR2AHTR2CMEN1KMT2A
SCHEMBL13345024 0.76 KDM4E (0.83) NOTUMHTR2AHTR2CMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120009142-A1 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2012-01-12 US disclosed
US-20110268698-A1 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2011-11-03 US disclosed
US-8013006-B2 Methods for treating hepatitis C PTC THERAPEUTICS, INC. (US) 2011-09-06 US disclosed
US-7973069-B2 Methods for treating hepatitis C PTC THERAPEUTICS, INC. (US) 2011-07-05 US disclosed
US-20100305100-A1 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2010-12-02 US disclosed
US-20100292187-A1 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2010-11-18 US disclosed
US-20080096928-A9 Indole compounds that modify translational control of Hepatitis C virus PTC THERAPEUTICS, INC. 2008-04-24 US disclosed
WO-2007084435-A2 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2007-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096928-A9 Indole compounds that modify translational control of Hepatitis C virus EIF2AK2, INMT, IDO1 NOTUM 1243/4885HTR2A 645/4885HTR2C 364/4885
US-20110268698-A1 METHODS FOR TREATING HEPATITIS C HAVCR2, LIPC, HCCS NOTUM 833/4885HTR2A 3904/4885HTR2C 2510/4885
US-20120009142-A1 METHODS FOR TREATING HEPATITIS C OAT, HAVCR2, HCCS NOTUM 478/4885HTR2A 3927/4885HTR2C 3217/4885
US-20100292187-A1 METHODS FOR TREATING HEPATITIS C HAVCR2, EIF2AK2, MAVS NOTUM 3153/4885HTR2A 4616/4885HTR2C 4031/4885
US-20100305100-A1 METHODS FOR TREATING HEPATITIS C HAVCR2, EIF2AK2, MAVS NOTUM 3153/4885HTR2A 4616/4885HTR2C 4031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.